1. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES. (May 2023) Authors: Savona, M.; Mccloskey, J.; Griffiths, E.; Yee, K.; Zeidan, A.; Al-Kali, A.; Deeg, H.J.; Patel, P.; Sabloff, M.; Keating, M.-M.; Zhu, N.; Gabrail, N.; Fazal, S.; Maly, J.; Odenike, O.; Kantarjian, H.; Dezern, A.; O'Connell, C.; Roboz, G.; Busque, L. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: PHASE 2 STUDY OF ORAL DECITABINE AND CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS). (May 2023) Authors: Zeidan, A.; Mosher, K.; Souza, S.; Mirakhur, B.; Taylor, J.; Keer, H. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS. (May 2023) Authors: Garcia-Manero, G.; Bachiashvili, K.; Griffiths, E.; Traer, E.; Saini, L.; Amin, H.; Zeidan, A.; Mohan, S.; Lübbert, M.; Maness, L.; Foran, J.; Selleslag, D.; Xicoy, B.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Berdeja, J.; Al-Ali, H.; Zhu, N.; Lopez, P. Font Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗